课题基金 / 基金详情

A Novel Formulation of the Anticancer Drug Candidate CX5461 that Relies on Metal Chemistry and Liposomal Nanotechnology: Development for use in Treatment of Pancreatic Cancer's with BRCA Deficiencies; an Orphan Indication

A Novel Formulation of the Anticancer Drug Candidate CX5461 that Relies on Metal Chemistry and Liposomal Nanotechnology: Development for use in Treatment of Pancreatic Cancer's with BRCA Deficiencies; an Orphan Indication
依赖金属化学和脂质体纳米技术的抗癌候选药物 CX5461 的新配方：开发用于治疗 BRCA 缺陷的胰腺癌；
批准号：
446517
负责人：
Bally Marcel B
金额：
$55.73万
依托单位：
BC Cancer, part of PHSA (Vancouver)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-04-01 至 2026-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=446517&lang=en
关键词：
Brca Deficiencies Cx5461 Drug Development Liposomes Metal Chemistry Mice Pancreatic Cancer Efficacy Models Preclinical Safety Pharmacology Skin Toxicity

项目摘要

项目成果

Bally Marcel B的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CX-5461 is an interesting anti-cancer drug candidate. It was originally developed as an agent that inhibits a protein that is important in producing RNA, the material in cells responsible for producing proteins. Since that time it has been shown to act as
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Copper Drug Complexes: Development of a novel class of drugs with significant potential for treatment of platinum insensitive cancers
  • 批准号：
    357858
  • 项目类别：
    Operating Grants
  • 资助金额：
    $35.67万
  • 财政年份：
    2016
  • 负责人：
    Bally Marcel B
  • 依托单位：
    BC Cancer, part of PHSA (Vancouver)
Identifying Cytoprotective Responses Triggered Following Initial Exposure to Targeted Therapy: Defining Improved Treatment Strategies for Patients with HER-2 Positive Breast Cancer.